In this review:
OPTIMA: test-directed therapy in ER+/HER2– early breast cancer
lidERA BC: results in pre/postmenopausal patients
SENOMAC: omission of complete axillary dissection after positive sentinel lymph node biopsy
AXSANA: predicting axillary response to neoadjuvant chemotherapy in node-positive breast cancer
Izalontamab brengitecan (iza-bren) in TNBC
SAKK 96/12 REDUSE: skeletal events with reduced denosumab dosing
ASCENT-03: PFS2 with SG vs. chemotherapy in TNBC
TROPION-Breast02: additional efficacy endpoints
OASIS-4: sleep & QoL with elinzanetant across endocrine therapy types
SERENA-6: camizestrant for emergent ESR1 alterations in advanced breast cancer
Please login below to download this issue (PDF)